Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants.
作者信息
Wang Yu, Zhao Danyang, Liu Xinbing, Chen Xubo, Xiao Wenying, Feng Liuliu
机构信息
Department of Cardiology, Shidong Hospital, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
出版信息
J Med Virol. 2023 Jan;95(1):e28443. doi: 10.1002/jmv.28443.
Abstract
摘要
相似文献
1
Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants.尽早服用帕罗韦德可缩短感染新冠病毒奥密克戎变异株患者的病毒清除时间。
J Med Virol. 2023 Jan;95(1):e28443. doi: 10.1002/jmv.28443.
2
The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial.帕罗韦德对感染新型冠状病毒奥密克戎变异株老年患者的疗效：一项非随机临床试验的结果
Front Med (Lausanne). 2022 Sep 6;9:980002. doi: 10.3389/fmed.2022.980002. eCollection 2022.
3
Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2.与感染奥密克戎 BA.2.2 的老年患者病毒持续排出相关的因素。
Front Public Health. 2023 Jan 12;10:1087800. doi: 10.3389/fpubh.2022.1087800. eCollection 2022.
4
Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report.奥密克戎 BA.2 引起的 COVID-19 老年患者使用帕罗韦德治疗：一例报告。
Medicine (Baltimore). 2022 Nov 11;101(45):e31361. doi: 10.1097/MD.0000000000031361.
5
Association between immunity and viral shedding duration in non-severe SARS-CoV-2 Omicron variant-infected patients.非重症奥密克戎变异株 SARS-CoV-2 感染患者的免疫与病毒脱落持续时间的关系。
Front Public Health. 2022 Dec 22;10:1032957. doi: 10.3389/fpubh.2022.1032957. eCollection 2022.
6
Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.奥密克戎变异株再次感染对先前感染仓鼠的影响。
J Virol. 2023 Jan 31;97(1):e0136622. doi: 10.1128/jvi.01366-22. Epub 2023 Jan 12.
7
Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients.新型冠状病毒德尔塔株和奥密克戎变异株感染患者肝损伤的临床特征及相关预测因素。
Eur J Gastroenterol Hepatol. 2022 Sep 1;34(9):933-939. doi: 10.1097/MEG.0000000000002381. Epub 2022 Apr 29.
8
Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study.儿童感染前奥密克戎变异株后对关注的 SARS-CoV-2 变异株的抗体反应：一项观察性队列研究。
EBioMedicine. 2022 Sep;83:104230. doi: 10.1016/j.ebiom.2022.104230. Epub 2022 Aug 18.
9
Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant.与德尔塔变异株相比，奥密克戎变异株的病毒载量较低，导致快速抗原检测的敏感性降低。
Microbiol Spectr. 2022 Oct 26;10(5):e0192222. doi: 10.1128/spectrum.01922-22. Epub 2022 Sep 20.
10
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.加利福尼亚州 2021 年 12 月至 2022 年 5 月辉瑞公司新冠口服药 Paxlovid 治疗后因 COVID-19 住院和急诊就诊情况。
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833. doi: 10.15585/mmwr.mm7125e2.
引用本文的文献
1
A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19.一项关于氯硝柳胺纳米复合物治疗轻至中度新型冠状病毒肺炎患者的随机、双盲、安慰剂对照试验。
Nat Commun. 2025 Aug 1;16(1):7084. doi: 10.1038/s41467-025-62423-4.
2
Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19.阿兹夫定与奈玛特韦/利托那韦治疗新冠肺炎住院患者的有效性和安全性
BMC Infect Dis. 2025 May 14;25(1):701. doi: 10.1186/s12879-025-11007-0.
3
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series.延长疗程的口服奈玛特韦/利托那韦对确诊的长新冠的影响：病例系列
Commun Med (Lond). 2025 Jan 6;4(1):261. doi: 10.1038/s43856-024-00668-8.
4
A multicenter randomized control trial: Point-of-care syndromic assessment versus standard testing in urgent care center patients with acute respiratory illness.一项多中心随机对照试验：急诊中心急性呼吸道疾病患者的即时护理综合征评估与标准检测对比
J Am Coll Emerg Physicians Open. 2024 Oct 23;5(5):e13306. doi: 10.1002/emp2.13306. eCollection 2024 Oct.
5
A narrow ratio of nucleic acid to SARS-CoV-2 N-protein enables phase separation.核酸与新冠病毒N蛋白的狭窄比例能够实现相分离。
J Biol Chem. 2024 Nov;300(11):107831. doi: 10.1016/j.jbc.2024.107831. Epub 2024 Sep 27.
6
Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study.奈玛特韦-利托那韦（帕罗韦德）治疗发病超过5天的COVID-19患者的真实世界有效性和安全性：一项回顾性队列研究。
Front Pharmacol. 2024 Aug 19;15:1401658. doi: 10.3389/fphar.2024.1401658. eCollection 2024.
7
Clinical feature of omicron infection in children with inborn errors of immunity in China.中国先天性免疫缺陷患儿感染奥密克戎的临床特征。
Front Immunol. 2024 Jul 23;15:1420547. doi: 10.3389/fimmu.2024.1420547. eCollection 2024.
8
Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions.美国服用其奈玛特韦/利托那韦处方的患者比例。
Infect Dis Ther. 2024 Sep;13(9):2035-2052. doi: 10.1007/s40121-024-01023-z. Epub 2024 Aug 3.
9
Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study.奈玛特韦片/利托那韦片用于发病 5 天以上的重症或危重症 COVID-19 住院患者：一项倾向评分匹配、多中心、回顾性队列研究。
BMC Infect Dis. 2024 Jun 18;24(1):597. doi: 10.1186/s12879-024-09150-1.
10
A narrow ratio of nucleic acid to SARS-CoV-2 N-protein enables phase separation.核酸与新冠病毒N蛋白的比例狭窄会导致相分离。
bioRxiv. 2024 Apr 11:2024.04.10.588883. doi: 10.1101/2024.04.10.588883.
本文引用的文献
1
Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.用于免疫功能低下且因感染新型冠状病毒而住院的患者的帕罗韦德。
Lancet Infect Dis. 2022 Sep;22(9):1279. doi: 10.1016/S1473-3099(22)00430-3. Epub 2022 Jul 14.
2
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.加利福尼亚州 2021 年 12 月至 2022 年 5 月辉瑞公司新冠口服药 Paxlovid 治疗后因 COVID-19 住院和急诊就诊情况。
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833. doi: 10.15585/mmwr.mm7125e2.
3
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.帕克洛维德降低高危患者的严重 2019 冠状病毒病和死亡率的有效性。
Clin Infect Dis. 2023 Feb 8;76(3):e342-e349. doi: 10.1093/cid/ciac443.
4
Nirmatrelvir Plus Ritonavir: First Approval.奈玛特韦片/利托那韦片：首次获批。
Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5.
5
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
Zotero 插件